Endocrine Abstracts

Introduction: In recent years, there has been a significant increase in the detection of thyroid cancer (TC) and a number of thyroid surgeries. Both the ATA 2015 and 2022 Polish guidelines allow sparing treatment in low-risk TC, nevertheless, most patients are qualified for total thyroidectomy.Material and method: The present study analyzed how often a TC patient opts for sparing treatment and the relationship between the size of the primary focus and ri...

Endocrine cancer constitutes a term and simultaneously a definition of a type of cancer, that is common in American literature whereas so far absent in European nomenclature. Detailed analysis of scientific programs of European endocrinological and oncological congresses proves that also these societies do not mention this type of cancer. To change this unfavorable situation a new clinical platform called European Task Group for Endocrine Cancer (ETEC), working under the auspi...

Introduction: The importance of telomerase reverse transcriptase promoter (TERTp) mutations in DTC is widely discussed. It has been demonstrated that the presence of TERTp mutations is associated with higher cancer aggressiveness, reflected by lymph node metastases, distant metastases, advanced tumor stage, recurrence, and even disease-specific mortality. Nevertheless, there is no clear evidence-based data demonstrating how to manage these patients. Therefore...

Calcitonin assessment in thyroid diseases is recommended when medullary thyroid cancer (MTC) is suspected in fine needle biopsy, as well as in ‘suspicious for a follicular neoplasm’ class, especially oxyphilic type, in patients with germinal RET proto-oncogene mutation and in nondiagnostic biopsy when no surgical treatment is planned. This assessment is also suggested before any planned thyroid surgery to exclude MTC. Beyond diagnosis confirmation it is also suggeste...

The treatment with multi kinase inhibitors (MKI) under clinical trials due to advanced thyroid cancer (TC) may postpone moving on the patients with advanced disease to the palliative care stage. However, chronic and escalating somatic symptoms during the treatment may promote the appearance of depressive reactions. It can be expected that a cognitive image of the disease, as a collection of subjective beliefs concerning patient’s own illness and treatment, will be an impo...

Neuroendocrine tumors are rare in young patients and usually have favorable course. We present a case of young, 13-year-old girl diagnosed with insulinoma. The diagnosis was stated on the basis of the presence of neuroglycopenic symptoms. An abdominal CT scan demonstrated a tumor localized in the head of pancreas. The patient received diazoxide as a preparation to surgery. Therapy was effective, but discontinued due to side effects. Patient underwent the Whipple operation. Dur...

Introduction: Systemic treatment of advanced progressing thyroid cancer (TC) is based on molecularly targeted therapy with tyrosine kinase inhibitors (TKIs), mainly inhibitors targeting vascular endothelial growth factor receptors (VEGFR). Such treatment is related to numerous side effects. However, the relationship between TKIs and renal adverse events (RAEs) is unclear. VEGFR inhibitors are associated with proteinuria. In some patients, increased serum creatinine level and t...

Multi kinase inhibitors (MKIs) constitute a new therapeutic option in advanced RAI-refractory differentiated thyroid cancer (DTC) and medullary thyroid carcinoma (MTC). To date four different MKIs demonstrated a beneficial effect on progression free survival in DTC (sorafenib, lenvatinib) and MTC (vandetanib and cabozantinib). However, the treatment related toxicity, which potentially may limit their clinical use and lead to a negative impact on the quality of life, have been ...

Background: Although neuroendocrine tumours (NET) constitute a very heterogeneous group, most of them express somatostatin receptors that enable treatment with somatostatin analogues(SA), which proved to be effective both as bio- or radiopeptide therapy. However, little is now about combining this two treatment modalities.The aim of our prospective study was to evaluate results of radiolabeled somatostatin analogues (PRRT) with or without long lasting ‘cold’ SA as co...

Introduction: Mechanism of pathogenesis of pituitary adenomas is still unknown. Gene expression differences in pituitary cells of different origin are not extensively described. Identification of genes specific for pituitary adenomas should enable better understanding of differences in their response to therapy, especially to radiotherapy.Aim: The aim of our study was to evaluate the correlation of coexpression of distinct pituitary adenoma genes based o...